Clinical trial · Observational
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
The Prognostic Value of Circulating Plasma Cells Quantified by Multiparameter Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
NCT06228794CI-TRIAL-00089969recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Peripheral blood test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Newly diagnosed multiple myeloma cohort
- description
- Participants who meet the multiple myeloma diagnostic criteria of IMWG are eligible.
- interventionNames
- Other: Peripheral blood test
Primary outcomes (1)
- measure
- 2-year progression-free survival (PFS)
- timeFrame
- 2 years
- description
- To evaluate if there is a correlation between high CPCs level and poor PFS.
Secondary outcomes (2)
- measure
- Rates and depth of response
- timeFrame
- 2 years
- description
- To evaluate if there is a correlation between CPCs level and rates and depth of response (IMWG response criteria).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Patients must meet all of the following inclusion criteria. * Newly diagnosed multiple myeloma patients. * Patients without any previous anti-myeloma treatment. * Age: 18-80years old (adult). * No history of cancer. * Informed consent. Exclusion Criteria: Patients meeting any of the following exclusion criteria will not be included in the study. * Received therapy for multiple myeloma. * Patients diagnosed with monoclonal gammopathy of undetermined significance, smoldering myeloma, nonsecretory myeloma, plasma cell leukemia, amyloidosis, waldenstrom macroglobulinemia or POEMS. * Imminent or emerging infection. * Known to be seropositive for a history of HIV. * A participant is a woman who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial. * Known or suspected of not being able to comply with the study protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.